{
    "organizations": [],
    "uuid": "c96b790271c7d27ab134725c46f9b436139375e4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/buzz-aradigm-corp-ladenburg-thalmann-cut/buzz-aradigm-corp-ladenburg-thalmann-cuts-rating-to-neutral-idUSL4N1P7492",
    "ord_in_thread": 0,
    "title": "BUZZ-Aradigm Corp: Ladenburg Thalmann cuts rating to 'neutral'",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "** Drug developer’s shares plunge 42.7 pct to $1.96 premarket - top pct loser among all U.S.-listed stocks\n** Based on -ve Adcom vote on Thursday and resulting lack of clarity wrt regulatory pathway for Linhaliq, we’re lowering our rating to “neutral” from “buy”, removing PT - Ladenburg Thalmann\n** An advisory committee to U.S. FDA voted 12-3 against co’s drug, Linhaliq, as a treatment for non-cystic fibrosis bronchiectasis with a bacterial infection\n** FDA usually takes recommendations into account when making a drug approval, but is not obligated to follow them\n** We expect it is likely Aradigm will receive a complete response letter for Linhaliq by the Jan 26 action date set by the U.S. FDA - Ladenburg Thalmann\n** Company’s stock had risen more than four-fold in 2017 (Reporting by Akankshita Mukhopadhyay in Bengaluru)\n ",
    "published": "2018-01-12T21:51:00.000+02:00",
    "crawled": "2018-01-13T14:42:04.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "drug",
        "developer",
        "share",
        "plunge",
        "pct",
        "premarket",
        "top",
        "pct",
        "loser",
        "among",
        "stock",
        "based",
        "adcom",
        "vote",
        "thursday",
        "resulting",
        "lack",
        "clarity",
        "wrt",
        "regulatory",
        "pathway",
        "linhaliq",
        "lowering",
        "rating",
        "neutral",
        "buy",
        "removing",
        "pt",
        "ladenburg",
        "thalmann",
        "advisory",
        "committee",
        "fda",
        "voted",
        "co",
        "drug",
        "linhaliq",
        "treatment",
        "fibrosis",
        "bronchiectasis",
        "bacterial",
        "infection",
        "fda",
        "usually",
        "take",
        "recommendation",
        "account",
        "making",
        "drug",
        "approval",
        "obligated",
        "follow",
        "expect",
        "likely",
        "aradigm",
        "receive",
        "complete",
        "response",
        "letter",
        "linhaliq",
        "jan",
        "action",
        "date",
        "set",
        "fda",
        "ladenburg",
        "thalmann",
        "company",
        "stock",
        "risen",
        "reporting",
        "akankshita",
        "mukhopadhyay",
        "bengaluru"
    ]
}